Thank you for your interest in the COMPPARE study. Patient enrollment is now closed.
COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).”
This study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI) and approved by the University of Florida Institutional Review Board (IRB 201801001; PI: Nancy Mendenhall, MD), will compare the quality of life, side effects, and cure rates for prostate cancer patients treated with proton therapy or photon therapy.
About the study
Men between the ages of 30-80 across the US treated with either protons or photons were asked to participate in COMPPARE. Participants will answer brief surveys regarding treatment choice, quality of life, and side effects for at least 3 years. If you have questions about the study, please email the study team at email@example.com.